Telix Pharmaceuticals has announced positive early-stage results from its global phase 3 trial of TLX591, an experimental treatment for advanced prostate cancer. The initial phase of the trial, ...
FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
In much-needed good news for the radiopharmaceuticals group, Telix Pharmaceuticals (ASX:TLX) says the first stanza of its “highly innovative” phase III prostate cancer therapeutic trial has come up ...
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results